GlassScriptPhysician profile
Kim M Pierce
NPI 1659431104
$2,616.43
in general payments reported to CMS, 2019-2025
24 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $204 · 2021: $330 · 2022: $251 · 2023: $370 · 2024: $825 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,700.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $667.39 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $586.56 | 2019-2025 | |
| Glaxosmithkline, LLC. | $389.98 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $178.61 | 2019-2025 | |
| Lilly USA, LLC | $156.02 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $143.21 | 2022-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $76.65 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.90 | 2022 | |
| Shield Therapeutics INC | $39.01 | 2023 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.44 | 2023 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $37.76 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $33.20 | 2021-2025 | Camzyos |
| Biohaven Pharmaceutical Holding Company LTD. | $29.04 | 2022 | |
| Grifols USA, LLC | $24.36 | 2023 | Prolastin-C Liquid |
| Esperion Therapeutics, INC. | $22.94 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $21.83 | 2021 | |
| Amarin Pharma, INC. | $20.48 | 2020 | |
| Phathom Pharmaceuticals, INC. | $18.42 | 2025 | Voquezna |
| Ardelyx, INC. | $17.03 | 2024 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $15.59 | 2023 | |
| Janssen Pharmaceuticals, INC | $15.50 | 2021 | |
| Tactile Systems Technology INC | $15.03 | 2024 | Flexitouch Plus, Entre Plus |
| Acella Pharmaceuticals, LLC | $13.25 | 2024 | NP Thyroid 60 |
| Sanofi Pasteur INC. | $13.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.